ID: h-40d0524f
Hypothesis
Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["SLC16A1 MCT1<br/>Upregulation"]
B["Ketone Body<br/>Neuronal Import"]
C["Neuronal Energy<br/>Metabolism Restoration"]
D["Mitochondrial<br/>Function Support"]
E["Neuroprotective<br/>Energy State"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style E fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
Human AD prefrontal cortex shows 40-60% reduction in MCT1 and MCT4 protein expression compared to age-matched controls
Supports
Ketogenic diet intervention in MCI patients improves cognitive outcomes and increases serum ketone bodies
Supports
Mouse model of AD (APP/PS1) demonstrates that ketone supplementation improves mitochondrial function only when MCT expression is preserved
Contradicts
Ketogenic diets show limited CNS ketone uptake in humans - using 11C-acetoacetate PET, ketones enter brain but uptake saturates at physiological levels
Contradicts
Clinical trials of ketone esters in AD show modest brain uptake - cerebral metabolic improvement is limited
Contradicts
MCT1 has bidirectional transport function - upregulation could increase lactate efflux from neurons, potentially worsening energy balance
Contradicts
APP/PS1 mouse models may not recapitulate human AD ketone metabolism - species differences in MCT expression patterns are significant
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SLC16A1
No curated PDB or AlphaFold mapping for SLC16A1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SLC16A1 (MCT1) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SLC16A1 (MCT1).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0125
Events (7d)
1
Price History
▲6.4%💾 Resource Usage
LLM Tokens
38,010
$0.1140
Total Cost
$0.1140
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 3-month-old 3xTg-AD mice are treated with chronic MCT1 agonist (α-cyano-4-hydroxycinnamate at 10 mg/kg/day via osmotic pump) for 8 weeks, THEN brain tissue β-hydroxybutyrate concentration will incr | Brain BHB concentration increases from ~0.8 μmol/g to ≥1.12 μmol/g; latency to platform decreases from baseline ~45 sec to ≤33 sec on day 5 of Morris water maze | — no observation — | pending | 0.45 |
| IF human iPSC-derived neurons are transduced with SLC16A1 (MCT1) overexpression vector (AAV9-hSLC16A1), THEN 13C-beta-hydroxybutyrate uptake will increase by at least 50% within 72 hours compared to A | Neuronal 13C-BHB uptake rate increases from baseline ~2.5 nmol/mg protein/min to ≥3.75 nmol/mg protein/min (50% increase); intracellular ketone body metabolite | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF human iPSC-derived neurons are transduced with SLC16A1 (MCT1) overexpression vector (AAV9-hSLC16A1), THEN 13C-beta-hydroxybutyrate uptake will increase by at least 50% within 72 hours compared to AAV9-empty vector controls, as measured by LC-MS/MS isotope tracing.
Predicted outcome: Neuronal 13C-BHB uptake rate increases from baseline ~2.5 nmol/mg protein/min to ≥3.75 nmol/mg protein/min (50% increase); intracellular ketone body m
Falsification: No significant difference in 13C-BHB uptake between MCT1-overexpressing and control neurons (two-sample t-test p > 0.05) or uptake decreases rather than increases.
pendingconf 45%
IF 3-month-old 3xTg-AD mice are treated with chronic MCT1 agonist (α-cyano-4-hydroxycinnamate at 10 mg/kg/day via osmotic pump) for 8 weeks, THEN brain tissue β-hydroxybutyrate concentration will increase by ≥40% and spatial memory performance on Morris water maze will improve by ≥25% compared to ve
Predicted outcome: Brain BHB concentration increases from ~0.8 μmol/g to ≥1.12 μmol/g; latency to platform decreases from baseline ~45 sec to ≤33 sec on day 5 of Morris
Falsification: Brain BHB concentration shows no significant increase (ANOVA p > 0.05) OR Morris water maze performance does not improve (probe trial platform crossings < 2, latency ≥ 40 sec) despite MCT1 agonist tre
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.